Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/51080
Title: | Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: Comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay |
Authors: | Thor A. Wagner Catherine M. Kress Ingrid Beck Malee Techapornroong Pakorn Wittayapraparat Somboon Tansuphasawasdikul Gonzague Jourdain Nicole Ngo-Giang-Huong Marc Lallemant Lisa M. Frenkel |
Authors: | Thor A. Wagner Catherine M. Kress Ingrid Beck Malee Techapornroong Pakorn Wittayapraparat Somboon Tansuphasawasdikul Gonzague Jourdain Nicole Ngo-Giang-Huong Marc Lallemant Lisa M. Frenkel |
Keywords: | Medicine |
Issue Date: | 1-May-2010 |
Abstract: | A single dose of nevirapine (sdNVP) to prevent mother-to-child transmission of HIV-1 increases the risk of failure of subsequent NVP-containing antiretroviral therapy (ART), especially when initiated within 6 months of sdNVP administration, emphasizing the importance of understanding the decay of nevirapine-resistant mutants. Nevirapine-resistant HIV-1 genotypes (with the mutations K103N, Y181C, and/or G190A) from 21 women were evaluated 10 days and 6 weeks after sdNVP administration and at the initiation of ART. Resistance was assayed by consensus sequencing and by a more sensitive assay (oligonucleotide ligation assay [OLA]) using plasma-derived HIV-1 RNA and cell-associated HIV-1 DNA. OLA detected nevirapine resistance in more specimens than consensus sequencing did (63% versus 33%, P < 0.01). When resistance was detected only by OLA (n = 45), the median mutant concentration was 18%, compared to 61% when detected by both sequencing and OLA (n = 51) (P < 0.0001). The proportion of women whose nevirapine resistance was detected by OLA 10 days after sdNVP administration was higher when we tested their HIV-1 RNA (95%) than when we tested their HIV-1 DNA (88%), whereas at 6 weeks after sdNVP therapy, the proportion was greater with DNA (85%) than with RNA (67%) and remained higher with DNA (33%) than with RNA (11%) at the initiation of antiretroviral treatment (median, 45 weeks after sdNVP therapy). Fourteen women started NVP-ART more than 6 months after sdNVP therapy; resistance was detected by OLA in 14% of the women but only in their DNA. HIV-1 resistance to NVP following sdNVP therapy persists longer in cellular DNA than in plasma RNA, as determined by a sensitive assay using sufficient copies of virus, suggesting that DNA may be superior to RNA for detecting resistance at the initiation of ART. Copyright © 2010, American Society for Microbiology. All Rights Reserved. |
URI: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77951773576&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/51080 |
ISSN: | 00951137 |
Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.